서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 1 to 10 of 10

Issue DateTitle / Author(s) / CitationFileAltmetrics
2017-12
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
DOI
2020-01
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
DOI
2020-05
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
DOI
2021-07
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab
DOI
2022-01
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study
DOI
2022-02
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
DOI
2024-05
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
DOI
2024-05
Clinical practice guidelines for esophagogastric junction cancer: Upper GI Oncology Summit 2023

Kitagawa, Yuko; Matsuda, Satoru; Gotoda, Takuji; Kato, Ken; Wijnhoven, Bas; Lordick, Florian; Bhandari, Pradeep; Kawakubo, Hirofumi; Kodera, Yasuhiro; Terashima, Masanori; Muro, Kei; Takeuchi, Hiroya; Mansfield, Paul F.; Kurokawa, Yukinori; So, Jimmy; Monig, Stefan Paul; Shitara, Kohei; Rha, Sun Young; Janjigian, Yelena; Takahari, Daisuke; Chau, Ian; Sharma, Prateek; Ji, Jiafu; de Manzoni, Giovanni; Nilsson, Magnus; Kassab, Paulo; Hofstetter, Wayne L.; Smyth, Elizabeth Catherine; Lorenzen, Sylvie; Doki, Yuichiro; Law, Simon; Oh, Do-Youn; Ho, Khek Yu; Koike, Tomoyuki; Shen, Lin; van Hillegersberg, Richard; Kawakami, Hisato; Xu, Rui-Hua; Wainberg, Zev; Yahagi, Naohisa; Lee, Yeong Yeh; Singh, Rajvinder; Ryu, Min-Hee; Ishihara, Ryu; Xiao, Zili; Kusano, Chika; Grabsch, Heike Irmgard; Hara, Hiroki; Mukaisho, Ken-ichi; Makino, Tomoki; Kanda, Mitsuro; Booka, Eisuke; Suzuki, Sho; Hatta, Waku; Kato, Motohiko; Maekawa, Akira; Kawazoe, Akihito; Yamamoto, Shun; Nakayama, Izuma; Narita, Yukiya; Yang, Han-Kwang; Yoshida, Masahiro; Sano, Takeshi

Gastric Cancer, Vol.27 No.3, pp.401-425

DOI
2024-11
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 trial
DOI
2025-05
First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
DOI
1